[go: up one dir, main page]

AU2002235168A1 - Targeting pluripotent stem cells to tissues - Google Patents

Targeting pluripotent stem cells to tissues

Info

Publication number
AU2002235168A1
AU2002235168A1 AU2002235168A AU3516802A AU2002235168A1 AU 2002235168 A1 AU2002235168 A1 AU 2002235168A1 AU 2002235168 A AU2002235168 A AU 2002235168A AU 3516802 A AU3516802 A AU 3516802A AU 2002235168 A1 AU2002235168 A1 AU 2002235168A1
Authority
AU
Australia
Prior art keywords
targeting
tissues
stem cells
pluripotent stem
pluripotent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002235168A
Inventor
Bryon E. Petersen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Florida
Original Assignee
University of Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Florida filed Critical University of Florida
Publication of AU2002235168A1 publication Critical patent/AU2002235168A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2002235168A 2000-11-05 2001-11-05 Targeting pluripotent stem cells to tissues Abandoned AU2002235168A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24602800P 2000-11-05 2000-11-05
US60/246,028 2000-11-05
PCT/US2001/047225 WO2002036078A2 (en) 2000-11-05 2001-11-05 Targeting pluripotent stem cells to tissues

Publications (1)

Publication Number Publication Date
AU2002235168A1 true AU2002235168A1 (en) 2002-05-15

Family

ID=22929046

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002235168A Abandoned AU2002235168A1 (en) 2000-11-05 2001-11-05 Targeting pluripotent stem cells to tissues

Country Status (3)

Country Link
US (1) US20020094327A1 (en)
AU (1) AU2002235168A1 (en)
WO (1) WO2002036078A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2324839B1 (en) 2000-06-05 2017-08-09 The Trustees of Columbia University in the City of New York Granulocyte-colony-stimulating-factor (g-csf) for use in the treatment of myocardial infarct
IL146970A0 (en) * 2001-12-06 2002-08-14 Yeda Res & Dev Migration of haematopoietic stem cells and progenitor cells to the liver
US20030199464A1 (en) * 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
US20050271639A1 (en) * 2002-08-22 2005-12-08 Penn Marc S Genetically engineered cells for therapeutic applications
US20040161412A1 (en) * 2002-08-22 2004-08-19 The Cleveland Clinic Foundation Cell-based VEGF delivery
US9040676B2 (en) * 2003-08-11 2015-05-26 University Of South Florida Vigilant cells
US20060154860A1 (en) * 2004-07-22 2006-07-13 Ceradini Daniel J Manipulating stem-progenitor cell trafficking to injured tissue and/or tumors by altering HIF-1 and/or SDF-1 activity
US7429376B2 (en) * 2004-10-15 2008-09-30 University Of Louisville Research Foundation, Inc. Methods of screening for compounds that improve engraftment
US20090035318A1 (en) * 2005-09-29 2009-02-05 British Columbia Cancer Agency Branch Method and composition for increasing the engraftment efficiency of stem cells
US7696309B2 (en) 2006-10-23 2010-04-13 The Brigham And Women's Hospital, Inc. Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
ES2520044T3 (en) 2007-03-30 2014-11-11 The Cleveland Clinic Foundation SDF-1 for use in the treatment of ischemic peripheral vascular disorders
CA2709398C (en) * 2007-12-14 2017-11-07 The Cleveland Clinic Foundation Use of stromal cell-derived factor 1 for promoting wound healing
US20090246179A1 (en) * 2008-02-11 2009-10-01 The Cleveland Clinic Foundation Method of treating myocardial injury
EP2473196B1 (en) 2009-08-28 2017-05-31 The Cleveland Clinic Foundation Sdf-1 delivery for treating ischemic tissue
WO2011106234A1 (en) 2010-02-25 2011-09-01 Provasculon, Inc. Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
US10662234B2 (en) 2011-06-07 2020-05-26 Mesoblast International Sàrl Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived factor-1

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2117953C (en) * 1993-10-14 2001-12-11 Tasuku Honjo Human stromal derived factor 1 alpha and 1 beta and dnas encoding the same
MXPA00003885A (en) * 1997-10-22 2004-04-23 Inst Genetics Llc Chimeric polypeptides containing chemokine domains.
US20030113303A1 (en) * 1998-02-05 2003-06-19 Yitzhack Schwartz Homing of embryonic stem cells to a target zone in tissue using active therapeutics or substances

Also Published As

Publication number Publication date
WO2002036078A2 (en) 2002-05-10
US20020094327A1 (en) 2002-07-18
WO2002036078A3 (en) 2003-01-03

Similar Documents

Publication Publication Date Title
AU2001229731A1 (en) Human embryoid body-derived cells
AU2001280767A1 (en) Peptide-mediated delivery of molecules into cells
GB2375351B (en) Retrodifferentiation of cells to form undifferentiated cells
AU2002235168A1 (en) Targeting pluripotent stem cells to tissues
AU2002319054A1 (en) Multipotent stem cells from peripheral tissues and uses thereof
AU2001272995A1 (en) Stable liquid enzyme compositions with enhanced activity
AU2001279309A1 (en) Easy to hold container
AU2001284160A1 (en) Modulation of stem cell differentiation
AU2001292842A1 (en) Compositions and methods relating to prostate specific genes and proteins
AU2001260847A1 (en) Compositions isolated from skin cells and methods for their use
AU2001286315A1 (en) Stem cell-like cells
AU2001264763A1 (en) Human mesenchymal progenitor cell
AU2001295793A1 (en) Pluripotential stem cells
AU2001290078A1 (en) Stem cell therapy
AU2001247880A1 (en) Methods to prepare and use epidermal stem cells
AU2002245031A1 (en) Compositions and methods relating to prostate specific genes and proteins
AUPR041900A0 (en) Manipulation of plant cell walls
AU2001250966A1 (en) Pluripotential stem cells
AU2001294010A1 (en) Stem cells
AU2001275897A1 (en) Improvement of cell culture performance
AU2002217991A1 (en) Compositions and methods relating to prostate specific genes and proteins
AU2001255773A1 (en) Human caspase-14 compositions
AU2001247585A1 (en) Fail to pots architecture
AU2001269863A1 (en) Targeting viral vectors to specific cells
AU2001268399A1 (en) Toxicity typing using mesenchymal stem cells